Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise
Mark Speakman(Taunton & Somerset NHS Foundation Trust), Herman Stoevelaar(Barnes-Jewish Hospital), Bianca Meesen(Exmar (Belgium)), Emmanuel Chartier‐Kastler(Sorbonne Université), Gabriele Conti(University of Bologna), John Trachtenberg(Ministry of Health), Andrea Tubaro(Sapienza University of Rome), Michael P. O’Leary(University of California, Irvine), K. Dreikorn, Louis Smets, F. Desgrandchamps, Maite Pérez(Santa Casa Hospital), Franklin C. Lowe(St. Luke's-Roosevelt Hospital Center), J.E. Batista(Puigvert Foundation), R. Berges(Ruhr University Bochum)
Cited by 13
Related Papers
Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia
|The Lancet|1995|290
Urology practice during the COVID-19 pandemic
|Minerva Urologica e Nefrologica|2020|256
Adenocarcinoma of the Prostate
|Clinical practice in urology|1987|207
Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic?
|European Urology|2020|207
International Continence Society best practice statement for use of sacral neuromodulation
|Neurourology and Urodynamics|2018|173